Sumitomo Pharma Co Ltd (Sumitomo Pharma), formerly Sumitomo Dainippon Pharma Co Ltd, manufactures and sells pharmaceutical products, food additives, veterinary products, food ingredients and other products. The company classifies its operations into two business units, namely, Pharmaceutical and Others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sumitomo Pharma’s R&D focuses on the development of therapeutic agents in areas including psychiatry and neurology, regenerative medicine, cell therapy, infectious diseases and oncology. The company is advancing pipeline products targeted for the treatment of schizophrenia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), bipolar I depression, Alzheimer’s disease, prostate cancer, solid tumors, age-related mascular degeneration (AMD), uterine fibrosis, type 2 diabetes, and overactive bladder, among other indications. In FY2023, the company spent JPY131,858 million on its R&D activities, which as a percentage of revenue stood at 23.7% and grew 38.9% YoY. It conducts drug discovery research at three research facilities namely, Central Research Laboratories located at Suita, Osaka; Osaka Research Center at Konohana-ku, Osaka; and Regenerative & Cellular Medicine Kobe Center at Kobe, Japan. Sumitomo Dainippo also conducts R&D activities in collaboration with universities, research institutions and companies possessing innovative technologies. Its research partners include Kitasato Institutre; Healios K.K.; Center for iPS Cell Research and Application (CiRA) and Hitachi Ltd.; and Colombia University, Ehime University and National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN) among others. The company in collaboration with Save Medical Corp developing mobile applications for management of type 2 diabetic patients. There are new products in the development stage from Oncology, Psychiatry and Neurology, Regenerative Medicine & Cell Therapy, Infectious Diseases and Others such as ulotaront, SEP-4199, DSP-7888, EPI-589, RETHYMIC, Allogeneic iPS cell-derived photoreceptors, Lefamulin and malaria vaccines, Universal influenza vaccine along with the Latuda and Gemtesa.